Occult HBV Infection in Nigeria

  • O A Akintule
  • B A Olusola
  • Georgina Njideka Odaibo
  • Olufemi David Olaleye


Occult hepatitis B virus infection (OBI) is manifested by presence of HBV-DNA in the absence of detectable Hepatitis B surface antigen (HBsAg) with or without anti-HBV antibodies.  Hence it is a potential threat in blood transfusion medicine. This study was carried out to determine the prevalence of OBI as well as evaluate the effectiveness of using Hepatitis B surface antigen (HBsAg) marker alone in the diagnosis of HBV infection among HBsAg negative blood donors in Ilorin, Nigeria. A purposive sampling, including samples from 206 already donated and prescreened blood units from HBsAg negative from apparently healthy volunteer blood donors at the General Hospital Blood Transfusion Centre, Ilorin, Nigeria, were collected for further laboratory analysis for this study. Five millilitres of blood was collected and plasma sample tested for the presence of HBsAg using a commercially available ELISA kit. In addition, Polymerase Chain Reaction (PCR) was used for molecular detection of HBV DNA in each of the samples. Data was analyzed using descriptive statistics, Chi square at p = 0.05.  Of the 206 HBsAg Micropoint® rapid kits pre-screened seronegative samples collected from the blood transfusion centre, 8 (3.9%) samples were positive for the presence of HBsAg when retested using ELISA in the laboratory. Eighteen of the 206 samples (8.7%) were HBV-DNA positive by a semi-nested PCR technique giving an OBI rate of 8.7%. Out of the 18 HBV-DNA positive samples, 17 (4.4%) were from males and only one (5.6%) was from a female donor. Analysis of the 18 HBV DNA positive samples using genotype specific primers into genotype A and Non-A showed that 15 (83.3%) were HBV genotype A, while 2 (11.1%) were genotypes other than A (Non-A), one (5.6%) sample had mixed genotypes (A & non-A). A prevalence of 8.7% OBI found in this study indicates substantial risk of post transfusion HBV infection in the study area in Nigeria. Hence, the need to include HBV DNA detection in the routine blood screening that is, using Nucleic Acid Testing (NAT) technique for transfusion safety in the country


Abou M.A., Eltahir Y.M., Ali A.S. (2009). Seroprevalence of HBV and HCV among blood donors in Nyala, South Dar Fur, Sudan. Virol J. 23(6):146.
Ajayi AO; Komolafe AO; Ajumobi K. (2007). Seroprevalence of hepatitis B surface antigenaemia among health care workers in a Nigerian tertiary health institution. Nig J Clin Pract; 10: 287-289.
Antar W., El Shokry M.H., Abd E.l., Hamid W.A., Helmy M.F. (2010). Significance of detecting anti-HBc among Egyptian male blood donors negative for HBsAg. Transfusion Medicine 20: 409–413.
Behzad- Behbehani A; Mafi- Nejad A; Tabei SZ; Lankareni KB; Torab A; Moaddeb A. (2006). Anti- HBC &HBV-DNA detection in blood donors negative for hepatitis B virus surface antigen in reducing risk of transfusion associated HBV infection. Indian J Med Res 123, pp 37-42.
Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P (2001). Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 34: 194–203.
Busch MP. (2004). Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol; 11(1):26-32.
Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, et al. (2008). Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. Journal of Hepatology 49: 537–547.
Candotti D, Lin CK, Belkhiri D, Sakuldamrongpanich T, Biswas S, Lin S, et al. (2012). Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. gutjnl-2011-301281.
Chemin I, Trepo C (2005). Clinical Impact of occult HBV infection. J Clinical Virol 34: Suppl.1: S15-S21.
Czaja Albert J (1993) Chronic Active Hepatitis: The Challenge for a New Nomenclature. Ann Intern Med 119: 510-517.
Erhabor O., Kwaifa I.K., Bayawa A.M., Isaac Z.I., Dorcas I., et al (2014). Comparison of ELISA and Rapid screening techniques for the detection of HBsAg among blood donors in Usmanu Danfodiyo University Teaching Hospital Sokoto, North Western Nigeria. J Blood Lymph 4: 124.
Esumeh FI, Ugbomioko D, Isibor JO. (2003). Seroprevalence of HIV and HBsAg in central hospital Benin city, Nigeria. J Med Lab Sci; 12(2):52–55.
Fang Y., Shang Q.L., Liu J.Y., Li D., Xu W.Z., Teng X., et al. (2009). Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. Journal of Infection, 58: 383–388.
Fashola F.A., Kotila T.R., Akinyemi J.O. (2009). Trends in transfusion transmissible viral infections from 2001–2009 in Ibadan, Nigeria. Intervirology; 51 (6):427–431.
Ferguson E., Farrell K., Lawrence C. (2008). Blood Donation is an act of Benevolence Rather Than Altruism. Health Psychology, 27, 327-336.
Fessehayle N., Naik D., Fessehaye T. (2011). Transfussion transmited infections-a retrospective analysis from the National blood transfusion service, Eritrea. Pan Afr Med J. 9. 40.
Forbi J.C., Vaughan G., Purdy M.A., Campo D.S., Xia G.L., Ganova-Raeva L.M., et al. (2010). Epidemic history and evolutionary dynamics of hepatitis B virus infection in two remote communities in rural Nigeria. PLoS One; 5:e11615.
Glynn S.A., Kleinman S.H., Schreiber G.B., Zuck T., McCombs S., Bethel J., Garratty G., Williams A.E. (2002). Motivations to donate blood: Demographic comparisons. Transfusion. 42(2) , p 216-225.
Guettouche, T. and Hnatyszyn, H. J. (2005). Chronic hepatitis B and viral genotype: the clinical significance of determining HBV genotypes. Antiviral Therapy 10:593– 604. 2005.
Hairul Aini H., Omar A. R., Hair-Bejo M and Aini I. (2008). Comparison of Sybr Green I, ELISA and conventional agarose gel-based PCR in the detection of infectious bursal disease virus. Microbiological Research 163.5:556–563.
Healy K, (2000). Embedded Altruism: Blood Collection Regimes and the European Union’s Donor Population. Princeton University.
Hinrichs A.1., Picker S.M., Schneider A., Lefering R., Neugebauer E.A., Gathof B.S. (2008). Effect of blood donation on well-being of blood donors. Transfus Med 18(1):40-8.
Hisham Ismail., Mohamed Soliman., Nahed Ismail (2010). Occult hepatitis B virus infection in Egyptian hemodialysis patients with or without hepatitis C virus infection. Journal of Pathology and Laboratory Medicine International , Volume 2, p 113-120.
Hodges M., Sanders E., Aitken C. (1998). Seroprevalence of hepatitis markers: HAV, HBV, HCV, and HEV amongst primary school children in Freetown Sierra Leone. West African J Med;17:3–7.
Huang CH, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, et al. (2012) Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol 57:720–729.S0168-8278(12)00363-7.
Iqbal H.S., Solomon S., Murugavel K.G., Solomon S.S., Balakrishnan P. (2005). Evaluation and diagnostic usefulness of domestic and imported enzyme-linked immunosorbent assay for the detection of HIV type 1 antibody in India. Clin Diagn Lab Immunol 12: 1425-1428.
Ito K., Yotsuyanagi H., Yatsuhashi H., Karino Y., Takikawa Y., Saito T., Arase Y., Imazeki F., Kurosaki M and Umemura T. (2014). Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 59:89–97.
Jutavijittum P, Andernach IE, Yousukh A, Samountry B, Samountry K, Thammavong T, et al. (2014) Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang 106: 31-37.
Kew M., Kramvis A., Francois G. (2005). Hepatitis B virus genotypes. Vaccine; 23:2409–2423.
Kurbanov F., Tanaka Y., Fujiwara K., Sugauchi F., Mbanya D., Zekeng L., et al. (2005). A new subtype (subgenotype) Ac (A3) of hepatitis B virus and recombination between genotypes A and E in Cameroon. J Gen Virol 86: 2047–2056.
Li L., Chen P.J., Chen M.H., Chak K.F., Lin K.S., Tsai S.J.L. (2008). A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 48: 1198–1206.
Lok ASF (2000), Hepatitis B infection: pathogenesis and management. Journal of Hepatology 32: 89–97.
Makuwa M., Souquiere S., Telfer P., Apetrei C., Vray M., Bedjabaga I., et al. (2006). Identification of hepatitis B virus subgenotype A3 in rural Gabon. J Med Virol 78: 1175–1184.
Manzin A., Salvoni G., Bagnarelli P., Menzo S., Carloni G., Clementi M. (1991). A single-step DNA extraction procedure for the detection of serum hepatitis B virus sequences by the polymerase chain reaction. J Virol Methods 32: 245–253.
Mekuria G., Ramesh S.A., Alberts E., Bertozzi T., Wirthensohn M., Collins G and Sedgley M. (2003). Comparison of ELISA and RT-PCR for the detection of Prunus necrotic ring spot virus and prune dwarf virus in almond (Prunus dulcis). Journal of Virology Methods 114.1: 65-69.
Moore C. (2013). Point-of-care tests for infection control: should rapid testing be in the laboratory or at the front line? Journal of Hospital Infection 85:1.
Motayo B.O., Faneye A.O., Udo U.A., Olusola B.A., Ezeani I., Ogiogwa J.I (2015). Seroprevalence of transfusion transmissible infections (TTI), in first time blood donors in Abeokuta, Nigeria. Afr Health Sci. 15(1): 19–24.
Mudawi H., Hussein W., Mukhtar M., Yousif M., Nemeri O., Glebe D., et al. (2014). Overt and occult hepatitis B virus infection in adult Sudanese HIV patients. Int J Infect Dis 29: 65–70. S1201-9712(14)01588-4.
Muktar HM, Suleman AM, Jones M. (2005). Safety of blood transfusion: prevalence of HBsAg in blood donors in Zaria, Northern, Nigeria. Nigerian Journal of Surgical Research.;7(3&4):290–292.
Mulders M.N., Venard V., Njayou M., Edorh A.P., Oyefolu A.O.B., Kehinde M.O., et al. (2004). Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. Journal of Infectious Diseases 190: 400–408.
Musa B., Bussell S., Borodo M.M., Samaila A.A., Femi O.L. (2015). Prevalence of hepatitis B virus infection in Nigeria, 2000-2013: A systematic review and meta-analysis. Niger J Clin Pract;18:163-72.
Nagalo B.M., Bisseye C., Sanou M., Kienou K., Nebie Y.K., et al. (2012). Seroprevalence and incidence of transmission tranmissible infectious diseases among blood donors from regional blood transfusion centers in Burkina Faso, West Africa. Trop Med Int Health. 17(2):247–253.
N'Dri-Yoman T, Anglaret X, Messou E, Attia A, Polneau S, Toni T, et al. (2010) Occult HBV infection in untreated HIV-infected adults in Cote d'Ivoire. Antivir Ther 15: 1029–1034.
Newman B.H (2003). Vasovagal reaction rates and body weight: findings in high- and low-risk populations.Transfusion 43: 1084 –1088.
Newman B.H (2006). Donor reactions and injuries from whole blood donation. Transfusion Med Rev 11: 64 –75.
Nna E., Mbamalu C., Ekejindu I. (2014). Occult hepatitis B viral infection among blood donors in South-Eastern Nigeria. Pathog Glob Health, 108: 223–228.
Nwokediuko S. C. (2011). Chronic Hepatitis B: Management Challenges in Resource- Poor Countries. Hepatology 11 .10: 786-763.
Odaibo G. N., Ola S. O. and Olaleye D. O. (2013). Hepatitis B Virus DNA in Patients with HBsAg in South Western Nigeria. Journal of Medical Virology 85:214–218.
Odemuyiwa SO, Mulders MN, Oyedele OI, Ola SO, Odaibo GN, Olaleye DO, et al. (2001), Phylogenetic analysis of new hepatitis B virus isolates from Nigeria supports endemicity of genotype e in west Africa. Journal of Medical Virology 65: 463–469.
Ola S.O., Anomneze E.E., Chukwuani C.M., Ojo O.S., Ndububa D.A., Onyenkwe B., Nasidi A. (2000). Interferon alfa-2a (Roferon-A) in the management of Chronic Hepatitis B infection: Results of an open prospective study in Nigerian patients. West Afri. Med. J. 19: 259-264.
Ola S.O., Otegbayo J.A., Odaibo G.N., Olaleye O.D., Olubuyide I.O. (2002). Serum hepatitis C virus and hepatitis B surface antigenaemia in Nigerian patients with acute icteric hepatitis. West Afr J Med; 21: 215-217.
Ola S.O., Otegbayo J.A., Odaibo G.N., Olaleye D.O., Olubuyide I.O., Summerton C.B. (2009). Occult HBV infection among a cohort of Nigerian adults. J Infect Dev Ctries 3: 442–446.
Olinger M. Christophe., Ve´ ronique Venard., Mounjohou Njayou., Akeeb O. Bola Oyefolu., Ibrahim Maı¨ga., Alain J. Kemp., Sunday A. Omilabu., Alain le Faou., Claude P. Muller. (2006). Phylogenetic analysis of the precore/core gene of hepatitis B virus genotypes E and A in West Africa: new subtypes, mixed infections and recombinations. Journal of General Virology, 87, 1163–1173.
Olokoba A.B., Salawu F.K., Danburam A., Desalu O.O., Olokoba L.B., et al. (2009). Viral Hepatitides in voluntary blood donors in Yola, Nigeria. European Journal of Scientific Research; 31(3):329–334.
Olotu A. Amadin A., Adesola O. Oyelese., Lateef Salawu., Rosemary A. Audu., Azuka P. Okwuraiwe., Aaron O. Aboderin. (2016). Occult Hepatitis B virus infection in previously screened, blood donors in Ile-Ife, Nigeria: implications for blood transfusion and stem cell transplantation. Virology Journal 13:76.
Opaleye, O. O., Oluremi, A. S., Atiba, A. B., Adewumi, M. O., Mabayoje, O. V., Donbraye, E., Ojurongbe, O. and Olowe, O. A. (2014). Occult Hepatitis B Virus Infection among HIV Positive Patients in Nigeria. Journal of Tropical Medicine 796121.
Opaleye O.O., Tong H.V., Bui Tien S., Fagbami A.H., Adekanle O., Ojurongbe O., et al (2015). Occult Hepatitis B Virus Infection in Nigerian Blood Donors and Hepatitis B Virus Transmission Risks. PLoS ONE 10(7): e0131912.
Panhotra B.R, Bahrani A, Joshi C.S, Hassan Z.U (2005). Occult hepatitis B virus infection among anti-HBc positive blood donors: Necessitates substitution of screening by HBVNAT. Journal of Infection 51: 263.
Prati D, Gerosa A, Porretti L (2006) Occult HBV infection and blood transfusion. Journal of Hepatology; 44: 818.
Raimondo G, Pollicino T, Cacciola I, Squadrito G (2007) Occult hepatitis B virus infection. J Hepatol 46: 160–170.
Raimondo G, Allain J.P, Brunetto M.R, Buendia M.A, Chen D.S, Colombo M, et al. (2008). Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49: 652–657.
Salihu I. (2013). Policies, processes and procedures to ensure safe blood for transfusion. The Medical Laboratory Scientist.;34 (1&2):6–12.
Samal J, Kandpal M, Vivekanandan P, (2012). Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 25: 142–163.
Setia S., Gambhir R. S., Kapoor V., Jindal G., Garg S and Setia S. (2013). Attitudes and Awareness Regarding Hepatitis B and Hepatitis C Amongst Health-care Workers of a Tertiary Hospital in India. Annual Medical Health Science Research 3.4:551–558.
Sunbul M. (2014). Hepatitis B virus genotypes: Global distribution and clinical importance. World Journal of Gastroenterology; 20.18: 5427–5434.
Susmita M., Srijita N., Subrata B., Salil S., Malay S. (2012). Performance and diagnostic usefulness of commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and HCV in India. Virology Journal 9: 290.
Toan, N.L., Song, L.H., Kremsner, P.G., Duy, D.N., Binh, V.Q. and Koeberlein, B. (2006). Impact of the hepatitis B virus genotype and genotype mixtures on thecourse of liver disease in Vietnam. Hepatology 43:1375-1384.
Trouern-Trend J.J., Cable R.G., Badon S.J.,et al.(1999). A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. Transfusion 39: 316 –320.
World Health Organization. Hepatitis B Global Infection rate. (2006). Available from: http://www.pkids.org/files/pdf/phr/02-09 globalhbv.pdf.
WHO (2015) Hepatitis B. Fact sheet N° 204
Section C (Clinical and Laboratory Research)